Clinical considerations for immune dysregulation and immunodeficiency in Down syndrome
Journal of Human Immunity · 07.09.2026 · 2 (5)
DOI: 10.70962/jhi.20260052 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Human Immunity, online erschienen am 15.07.2026. Verfasst von Melissa Gans und 13 weiteren Autor:innen. Beteiligte Einrichtung: Jackson Health System, University of Miami Miller School of Medicine, Miami, FL, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIAMS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Down syndrome (DS), the genetic condition caused by trisomy 21 (T21), is characterized by lifelong immune dysregulation leading to high rates of autoimmune disorders, elevated risk of complications from infections, immune hypersensitivity, and a unique form of immunodeficiency. It is now appreciated that DS shares key hallmarks with interferonopathies, with vast remodeling of all branches of the immune system, hypercytokinemia, and widespread autoantibody production. Here within, we review the existing literature with an emphasis on clinical considerations toward monitoring, management, and therapeutic opportunities. We highlight recent research advances that illuminate diagnostic approaches to evaluate immune dysregulation in DS. We also discuss the evidence supporting specific immunomodulatory strategies that could have multidimensional benefits in this population, including JAK inhibitors, intravenous immunoglobulin, and B cell–depleting agents.
Autor:innen und Institutionen
- Jackson Health System, University of Miami Miller School of Medicine, Miami, FL, USA.
- LSU Health Shreveport, Shreveport, LA, USA.
- Cleveland Clinic, Cleveland, OH, USA.
- Mayo Clinic Jacksonville, Jacksonville, FL, USA.
- UH Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
- Washington University in St. Louis School of Medicine, St. Louis, MO, USA.
ORCID-Profile: Melissa Gans, Juanita Valdes Camacho, Matthew Wyke, Kasama Manothummetha, Harry Lesmana, Jacqueline Squire, Joao Pedro Lopes, Erica G Schmitt, Hanadys Ale, Junghee J Shin, Natalia Chaimowitz, Carolyn Baloh, Dusan Bogunovic, Joaquin Espinosa
Förderung
- NIAID NIH HHS
- NIAMS NIH HHS
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- National Institute of Arthritis Musculoskeletal and Skin Diseases
- Global Down Syndrome Foundation
Zitieren
APA
Gans, M., Camacho, J. V., Wyke, M., Manothummetha, K., Lesmana, H., Squire, J., Lopes, J. P., Schmitt, E. G., Ale, H., J Shin, J., Chaimowitz, N., Baloh, C., Bogunovic, D., & Espinosa, J. (2026). Clinical considerations for immune dysregulation and immunodeficiency in Down syndrome. Journal of Human Immunity, 2(5). https://doi.org/10.70962/jhi.20260052
Vancouver
Gans M, Camacho JV, Wyke M, Manothummetha K, Lesmana H, Squire J, et al. Clinical considerations for immune dysregulation and immunodeficiency in Down syndrome. Journal of Human Immunity. 2026;2(5). doi:10.70962/jhi.20260052
BibTeX
@article{Gans2026,
author = {Gans, Melissa and Camacho, Juanita Valdes and Wyke, Matthew and Manothummetha, Kasama and Lesmana, Harry and Squire, Jacqueline and Lopes, Joao Pedro and Schmitt, Erica G and Ale, Hanadys and J Shin, Junghee and Chaimowitz, Natalia and Baloh, Carolyn and Bogunovic, Dusan and Espinosa, Joaquin},
title = {Clinical considerations for immune dysregulation and immunodeficiency in Down syndrome},
journal = {Journal of Human Immunity},
year = {2026},
volume = {2},
number = {5},
doi = {10.70962/jhi.20260052}
}
EUVIMED